CL2017003143A1 - Composición multi-péptido. - Google Patents

Composición multi-péptido.

Info

Publication number
CL2017003143A1
CL2017003143A1 CL2017003143A CL2017003143A CL2017003143A1 CL 2017003143 A1 CL2017003143 A1 CL 2017003143A1 CL 2017003143 A CL2017003143 A CL 2017003143A CL 2017003143 A CL2017003143 A CL 2017003143A CL 2017003143 A1 CL2017003143 A1 CL 2017003143A1
Authority
CL
Chile
Prior art keywords
combination
peptides
peptide composition
refers
specific peptides
Prior art date
Application number
CL2017003143A
Other languages
English (en)
Inventor
Mark Peakman
Original Assignee
King S College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King S College London filed Critical King S College London
Publication of CL2017003143A1 publication Critical patent/CL2017003143A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

<p>LA INVENCIÓN SE REFIERE A UNA COMBINACIÓN DE PÉPTIDOS ESPECÍFICA. LA COMBINACIÓN DE PÉPTIDOS PUEDE ESTAR PRESENTE EN UNA COMPOSICIÓN FARMACÉUTICAMENTE ACEPTABLE. LA COMBINACIÓN DE PÉPTIDOS PUEDE USARSE EN LA TERAPIA O PREVENCIÓN DE LA DIABETES TIPO 1 (DT1). LA INVENCIÓN TAMBIÉN SE REFIERE A UN MÉTODO PARA DIAGNOSTICAR O DETERMINAR LA EFICACIA DEL TRATAMIENTO, EL MÉTODO UTILIZA LA COMBINACIÓN DE PÉPTIDOS ESPECÍFICA.</p>
CL2017003143A 2015-06-10 2017-12-07 Composición multi-péptido. CL2017003143A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1510056.3A GB201510056D0 (en) 2015-06-10 2015-06-10 Multi-peptide composition

Publications (1)

Publication Number Publication Date
CL2017003143A1 true CL2017003143A1 (es) 2018-05-18

Family

ID=53785229

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003143A CL2017003143A1 (es) 2015-06-10 2017-12-07 Composición multi-péptido.

Country Status (26)

Country Link
US (1) US11400131B2 (es)
EP (1) EP3307298B1 (es)
JP (1) JP6969790B2 (es)
KR (1) KR20180023948A (es)
CN (1) CN107896494B (es)
AR (1) AR104947A1 (es)
AU (1) AU2016275295B2 (es)
BR (1) BR112017026537A2 (es)
CL (1) CL2017003143A1 (es)
CO (1) CO2017012986A2 (es)
EA (1) EA201890007A1 (es)
EC (1) ECSP18001655A (es)
ES (1) ES2778630T3 (es)
GB (1) GB201510056D0 (es)
HK (1) HK1253094A1 (es)
IL (1) IL256199B2 (es)
MA (1) MA41668A1 (es)
MX (1) MX2017015658A (es)
PE (1) PE20180450A1 (es)
PH (1) PH12017501918A1 (es)
PL (1) PL3307298T3 (es)
TN (1) TN2017000517A1 (es)
TW (1) TW201712027A (es)
UY (1) UY36722A (es)
WO (1) WO2016198887A1 (es)
ZA (1) ZA201707873B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063702A1 (en) * 1999-04-21 2000-10-26 Zycos Inc. Peptide epitopes recognized by disease promoting cd4+ t lymphocytes
US20030045467A1 (en) * 2001-01-05 2003-03-06 Tihamer Orban Autoantigen composition
PL1709070T3 (pl) * 2004-01-30 2014-01-31 King S College London Peptydy do leczenia chorób autoimmunologicznych
GB0402129D0 (en) * 2004-01-30 2004-03-03 King S College London Therapeutic and diagnostic peptides
EP1725254A4 (en) * 2004-02-04 2008-02-13 Univ Columbia ANTI-CD3 IMMUNOTHERAPY AND SPECIFIC ANTIGENS FOR THE TREATMENT OF AUTOIMMUNITY
EP2118309B1 (en) * 2006-12-29 2015-01-28 The Regents of the University of Colorado, a body corporate Diagnostic and therapeutic target for autoimmune diseases and uses thereof
EP2678448A4 (en) * 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS
WO2013128453A1 (en) * 2012-03-01 2013-09-06 Yeda Research And Development Co. Ltd. Regeneration of islet beta cells by hsp60 derived peptides

Also Published As

Publication number Publication date
HK1253094A1 (zh) 2019-06-06
TN2017000517A1 (en) 2019-04-12
KR20180023948A (ko) 2018-03-07
EP3307298B1 (en) 2020-01-15
MA41668A1 (fr) 2018-03-30
CA2984957A1 (en) 2016-12-15
ZA201707873B (en) 2019-05-29
TW201712027A (zh) 2017-04-01
US11400131B2 (en) 2022-08-02
UY36722A (es) 2017-01-31
CO2017012986A2 (es) 2018-03-09
AU2016275295B2 (en) 2021-12-09
CN107896494B (zh) 2021-09-03
AU2016275295A1 (en) 2017-12-07
EP3307298A1 (en) 2018-04-18
EA201890007A1 (ru) 2018-05-31
IL256199B2 (en) 2024-11-01
IL256199B1 (en) 2024-07-01
PL3307298T3 (pl) 2020-06-29
BR112017026537A2 (pt) 2019-11-12
IL256199A (en) 2018-02-28
JP2018524301A (ja) 2018-08-30
JP6969790B2 (ja) 2021-11-24
US20180221434A1 (en) 2018-08-09
MX2017015658A (es) 2018-08-15
GB201510056D0 (en) 2015-07-22
ES2778630T3 (es) 2020-08-11
PH12017501918A1 (en) 2018-03-19
WO2016198887A1 (en) 2016-12-15
ECSP18001655A (es) 2018-10-31
PE20180450A1 (es) 2018-03-05
AR104947A1 (es) 2017-08-23
CN107896494A (zh) 2018-04-10

Similar Documents

Publication Publication Date Title
CO2020003478A2 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
ECSP17029203A (es) Inhibidor de cinasa aurora a
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
WO2015095811A8 (en) Combination therapy with neoantigen vaccine
AR094970A1 (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
MX373268B (es) Compuestos ppar para uso en el tratamiento de enfermedades fibroticas.
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
MX2017015926A (es) Uso de derivados de bencimidazol para escape acido nocturno.
MX2019001577A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
MX2016011115A (es) Terapia inmunorreguladora contra autoinmunidad en diabetes tipo 1.
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
EA201790552A1 (ru) Применение элсиглутида для лечения мукозита желудочно-кишечного тракта, включая индуцированную химиотерапией диарею
MX2016008968A (es) Compuestos organicos.
EA201590678A1 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
CL2017003143A1 (es) Composición multi-péptido.
EA201991531A1 (ru) Способы лечения композициями линаклотида с отсроченным высвобождением
ES2721003T3 (es) Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis
MX2015017136A (es) Composicion para la administracion oral de magnesio, en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma.